Editorial
Copyright ©The Author(s) 2023.
World J Gastrointest Oncol. Feb 15, 2023; 15(2): 215-224
Published online Feb 15, 2023. doi: 10.4251/wjgo.v15.i2.215
Table 3 Ongoing clinical trials to improve response to immunotherapies targeting colorectal cancer
Strategy
NCT number
Intervention
Targeting tyrosine kinaseNCT04764006Surufatinib (VEGFR1, VEGFR2, VEGFR3, FGFR1, and CSF-1R inhibitor)
NCT04819516High-intensity focused ultrasound therapy; toripalimab (anti-PD-1 antibody)
NCT04963283Cabozantinib (anti-VEGFR2) plus nivolumab (anti-PD-1 antibody)
Targeting TGF-βNCT03724851TEW-7197 (TGF-β receptor ALK4/ALK5 inhibitor)
Targeting Wnt signalingNCT02521844ETC-159 (Porcupine inhibitor) plus Pembrolizumab (anti-PD-1 antibody)
Combination with chemotherapyNCT04301557Pembrolizumab plus binimetinib (MEK 1/2 inhibitor) plus FOLFOX plus irinotecan
NCT04895137FOLFOX6 plus bevacizumab (anti-VEGF A) plus anti-PD-1 antibody
NCT03374254Anti-PD-1 antibody plus oxaliplatin plus capecitabine plus radiotherapy then mesorectal excision
Cancer vaccineNCT04046445ATP128 (chimeric recombinant protein vaccine) plus BI754091 (IgG4Pro antibody inhibitor) plus VSV-GP128 (recombinant vesicular stomatitis virus)
NCT04117087KRAS peptide vaccine plus nivolumab (anti-PD-1 antibody) plus ipilimumab (anti-CTLA4 inhibitor)
NCT04912765Neoantigen dendritic cell vaccine plus nivolumab